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INTRODUCTION  
World wide carcinoma is diagnosed annually in 10 million people.    
 
Oral Cavity Carcinoma accounts for 2,74,000 newly diagnosed 
Carcinoma in World annually.    
 
Oral cavity is the 6th most common carcinoma in the world.  Lung, 
Stomach and prostate (In males), Breast, Cervix and colorectum (In Females) 
are the top three carcinomas in the world.    
 
In well developed countries the incidence rate of oral cavity is less 
when compared to developing countries.  
 
In south central Asia (India) oral cavity is the commonest in male and 
cervix is the commonest in Female.   
 
According to National Cancer Registry Programme – District-wise 
comparison of age specific incidence – Thanjavur stands 11th place for oral 
cavity Carcinoma in male in India (Fig-1).  
 
Comparison to world, developed, developing and central Asia there is a 
wide difference in the incidence of oral cancer.  High incidence is probably 
due to socio economic factors habits, ignorance, late detection and lack of 
awareness.  
 
Even though oral cancers are easily accessible for physical 
examination and Biopsy, majority reported for treatment only at the later 
stages.   Cure rate is high if patients are treated in the early stages.     
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Knowing the magnitude of the problem a study is undertaken to know 
about the incidence in rural agro based districts from which patients attend 
our hospital (Fig – 2)  
 
A Prospective epidemiological analysis of oral cavity cancer and their 
outcomes for the period from June 2005 to September 2007 are discussed. 
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AIM OF STUDY 
 
 To analyse the incidence (Age, Sex, Occupation, Site and Histology) of 
oral cavity cancers in our Institution during the period 2005-2007. 
 
 To determine the etiological factors that influences the development of 
oral cavity cancers in this region.  
 
 To discuss the clinical presentation. 
 
 Discussion of various modalities of treatment and their outcomes.  
 
 Preventive aspects of Oral Carcinoma.  
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HISTORICAL REVIEW  
Ebers Papyres (1500 BC) – Eating ulcers of the gun. 
   
Pimpernelle – 1658 – First Hemiglossectomy for 
Benign lesion 
   
Marchetti – 1664 – Excision of the tumor in 
carcinoma tongue. 
   
F. Ruysch – 1734 – Traumatic genesis for 
Carcinoma tongue was 
proposed 
   
Lorenz Heister – To obtain a cure it was 
necessary to remove a margin 
of Normal tissue with the tumor. 
   
In Eighteenth century – German surgeons accepted 
glossectomy as the procedure 
of choice in treatment of cancer 
tongue  
   
Astley P.C. – 1914 – Intratracheal insuffilation 
anaestheia for Excision of 
Entire tongue.  
   
Theoder Fricke – 1898 – Operation for cancer of the lip. 
   
A.B. Johnson & Joseph D. Bryant – Malgagnes operation for 
Carcinoma lip. 
   
Crile – 1906 – Described the Block dissection 
with removal of all Nodes and 
Lymph bearing areolar tissue. 
   
J.C. Stewart – 1910 – Radical operation must include 
removal of the tissue adjacent 
to the growth and associated 
Lymph Nodes. 
   
A.C. Broders – 1920 – of Mayo Clinic reported males 
and smokers are at higher risk 
when compared to Females 
and non smokers.  
   
George Brewer – 1923 – Incidence of Lower lip is more 
than upper lip. 
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Neck dissection  
Grant ward & Haynis Martin 
– 1940 
– Commando’s operation performed 
in Memorial Hospital Newyork 
   
Mccammon and Shah   – Radical Neck dissection. 
   
Boccas – 1960’s – Modified Radical Neck dissection 
Type – 3 
   
Medina & Byres – Selective neck dissection (I–III) 
   
Khaiff – Selective neck dissection  
(II–IV) 
   
Weber – Selective neck dissection (VI) 
 
Radiotherapy  
Henry Bequeral – 1897 – Discovered Radiation 
   
Pierre curie & Mary curie 
– 1898 
– Discovered Radium. 
   
1930 – Introduction of Brachytherapy 
   
1950  – Teletherapy used with Cobalt 60 
   
1980’s – Supplementation with Megavoltage 
Radiotherapy  
 IMRT (Intensity Modulated RT) Latest Concept. 
Chemotherapy  
1970’s – Role of Adjuvant Chemotherapy 
   
Mccomb & Felteher Moore – 
1980’s 
– Combined Surgical & Radio 
therapy techniques  
 
Reconstruction  
Karl Thiersch  – 1874 – Free skin graft 
   
John Wolfe – 1875 – Full thickness graft 
   
1960’  – Regional flaps introduced 
   
Aryan – 1979 – Pectoralis Major Musculocutaneous 
flap. 
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Free Flaps  
In China – Radial Forearm flap 
   
Heyden & Miller – 1983 – Lateral Thigh flap 
 
 
Molecular targeted therapies  
  Slaughter described field cancerization in the molecular Biology of oral 
cavity squamous cell carcinoma. 
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ANATOMY OF ORAL CAVITY  
 
 Oral cavity encompasses the area from the vermillion border of the lip 
to an Imaginary line drawn between Hard and Soft Palate, and the 
circumvallate Papillae Inferiorly.   7 Anatomical sites are included in the oral 
cavity.  
 
1) Lip  
2) Buccal mucosa 
3) Upper & Lower alveolar ridge 
4) Floor of Mouth 
5) Anterior 2/3 of Tongue 
6) Retromolar Trigone 
7) Hard Palate.  
 
Lip: Lips are composed of the orbicularis oris muscle with skin on the 
external surface and mucous membrane covers the internal surface. 
 Transition from skin to mucous membrane of the oral cavity is the lip 
vermillion. 
 
Floor of Mouth  
 Floor of mouth is ‘U’ shaped area bounded by the Lower gum and oral 
tongue.    
 Terminates posteriorly at the insertion of anterior tonsillar pillar into the 
tongue.  
 Paired sublingual glands lies beneath the mucous membrane. 
 Whartons duct (Duct of Submandibular gland opens in the floor of 
mouth). 
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Tongue  
 Mobile Anterior 2/3 of tongue anterior to circumvallate papillae is 
considered as a part of oral cavity, posterior to circumvallate papillae is called 
as oropharynx.  
 
Buccal Mucosa  
 Buccal mucosa is the mucous membrane covering the Inner surface of 
lips & cheek ending below and above with transition to the gingiva, and it ends 
posteriorly at the Retromolar Trigone.   Parotid duct opens into the buccal 
mucosa at the upper second Molar tooth.  
 
Upper and Lower Alveolar Ridge 
Upper alveolar ridge extends from buccal sulcus to Hard Palate and 
extends up to superior end of Pterigopalatine arch posteriorly. 
Lower Alveolar ridge includes the Mucosa covering the Mandible from 
the gingivo buccal gutter to the origin of mobile mucosa in the floor of mouth.  
 
Both include the mucosal covering of the alveolar process of Maxilla 
and Mandible. 
 
Retro molar Trigone  
  Behind the third molar tooth a small triangular surface is called 
Retromolar Trigone.  
 
Base of the triangle - Last molar tooth.  
Apex – Terminates at Maxillary tuberosity. 
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Posterior 
triangle 
Hard Palate 
It serves as a partition between Nasal and oral cavities.  
Anterior 2/3 formed by palatine process of Maxilla.  
Posterior 1/3 formed by Horizontal plate of Palatine Bone.   
It drains mainly into upper deep cervical and retropharyngeal nodes.  
 
Neck Nodes  
Level I - I-A Sub mental  
  - I-B Submandibular  
 
Level II  - Extending from skull base to Carotid Bifurcation   
   IIA – Anterior to Spinal accessory.  
   IIB – Posterior to spinal accessory  
 
Level III -  Extending from Carotid Bifurcation to Omohyoid  
Muscle 
 
Level IV - Extending from omohyoid Muscle to Clavicle  
 
Level V  - VA Superior to the level of cricoid cartilage                  
                                 VB  Inferior to the level of cricoid cartilage  
 
Level VI - (Pretracheal & Prelaryngeal) – Central group  
 
Level VII - Superior Mediastinum.   
 
Level VIII - Retropharyngeal Nodes of Rouviere – lymphnodes   
Posterior to Naso and oropharynx.  
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Oral Cavity – Lymphatic drainage  
1. Lips Submandibular, preauricular and facial nodes 
2. Buccal mucosa Submaxillary and submental nodes 
3. Gingiva Submaxillary and jugulodigastric nodes 
4. Retromolar trigone Submaxillary and jugulo-digastric nodes 
5. Hard palate Submaxillary and upper jugular nodes 
6. Floor of mouth Submaxillary and jugular (middle and upper) nodes 
7. Anterior two thirds of the tongue Submaxillary and upper jugular nodes 
 
EPIDEMIOLOGY OF ORAL CAVITY CANCERS 
 
Incidence  
 In western world it forms 2 – 4% of all newly detected cancers. 
More than 90% are primary oral malignancy (ie) Squamous cell 
carcinoma.  
Age  
 90% of oral cavity cancer appears over the age of 40 yrs and            
65 yrs is the average age at diagnosis.    
 Mean age of survival is around 5 yrs from the time of diagnosis. 
 Mean age of death is around 68 yrs.  
 
Sex 
 Male to female ratio is 2.2 : 1 
 Men > women: 2-4 times increased risk for men than women for 
all racial / ethnic groups except for Filipinos, where the risk is 
equal for both male and female.  
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Race (Ethnic) Origin  
 Before the age of 55 Yrs.   Oral cavity – carcinoma is the 6th 
most common carcinoma in whites and in blacks it is the 4th 
most common carcinoma.  
 Lip and Salivary gland tumors are more common in white 
Americans than Black Americans.  
 When Compared to U.S.A. higher rates of oral cavity Cancers 
are reported in India, South East Asia, Hungary and Northern 
France.  
 
SECOND PRIMARY CARCINOMA  
 Second Primary carcinoma is defined as Synchronous (Different 
sites within 6 Months) (Or) Metachronous (different sites after 6 
months) (or) same site after 3 years of Malignancy.  
 Risk of second Carcinoma is more pronounced among patients 
younger than 60 years of age.  
 
MOLECULAR BIOLOGY OF ORAL CAVITY SQUAMOUS CELL 
CARCINOMA 
 
 New exciting field which throws more light on the pathogenesis of oral 
cavity cancer. Dysregulation of the molecular processes that underline 
tumorogenesis and metastasis in oral cavity squamous cell carcinoma.  
 
Three of these Mechanisms are  
1. Field Cancerisation  
2. Genetic progression  
3. Cancer Controlling genes 
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1) Field Cancerisation  
 Slaughter and Colleagues had described this phenomenon.  
Regions of grossly normal mucosa with chronic exposure to environmental 
mutagens in tobacco and Alcohol (or) Infection with HPV Contribute to the 
development of dysplastic mucosa.  
 
2) Genetic Theory  
 Genetic alteration in histologically normal tissues and in premalignant 
lesion  includes  a) Loss of Heterozygosity  
   b) Activation of Telomerase 
   c) DNA – Hyper Methylation. 
3) Cancer controlling genes 
a) Oncogenes: Hyper functionality of these carcinogens directly 
contribute to malignant process. 
In Oral Cavity Squamous Cell Carcinoma involved genes  
1) EGFR (Endothelium derived Growth Factor Receptor)  
2) STAT – 3 (Signal Transducer and activator of Transcription Family) 
b) Tumor suppressor genes  
 Loss of both alleles of a tumor suppressor gene through mutation, 
deletion results in alteration of cellular Homeostasis (Knudson – Two hit 
Hypothesis) 
 
 
c) Stability genes  
 House keeping of the cells DNA has been termed as stability genes. 
Mutation (or) Non-functionality results in carcinogenesis.  FANCA gene has 
genetic predisposition for oral cavity carcinoma. 
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Hanahan & weinburg suggested certain alteration in physiological 
process such as autonomy in growth signaling, invasion of apoptosis, 
unresponsiveness to growth inhibitor signaling, limitless replication, 
angiogenesis, invasion and metastasis are the molecular changes in 
carcinogenesis.  
 
GENETIC CHANGES IN ORAL CARCINOGENESIS  
1) EGFR/TGF – 2α  – Increased production 
2) TP53 gene   – Loss of P53 gene 
3) TP 16 & cyclin D1  – Activation 
4) BAX – proapoptic  – Decreased 
BCL2 – anti apoptic – Increased  
 
 Understanding of the above molecular biology has led to therapeutic 
strategies that target dysregulated processes in tumor microenvironment. 
 
RISK FACTORS 
1) Tobacco: contains more than 300 carcinogens. Tobacco consumed in 
2 ways 
a) smoking tobacco 
b) smokeless tobacco or spit tobacco 
a) Smoking tobacco: Consumed in the form of cigarette, beedi and 
kreteks. Carcinogens increase the relative risk by causing mutations 
that disrupt the cell cycle regulation or through an effect in the immune 
system 
b) Spit tobacco or smokeless tobacco: 
Used in 3 forms 
in poorly differentiated 
carcinoma 
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Chew – Leafy form of tobacco used with betel leaf & lime 
Plug – That has been compressed in to brick form and consumed  
Snuff – powdered form of tobacco usually sold in tins or flat cans.     
It causes hyperkeratosis, dysplasia and squamous cell carcinoma 
 
Tobacco Contains Aromatic Hydrocarbons, Benzpyrene and Tobacco 
Specific Nitrosamines act locally on the stem cell and Interfere with DNA 
synthesis.   
Relative Risk is 8 times (or) more.  
 
Alcohol  
 Alcohol particularly hard liquor incidence is 6 times more common 
among drinkers than non drinkers.  
 Alcohol and smoking have a synergistic effect. 
 Pooling of Saliva with carcinogens results in oral cavity cancer. 
 Extreme alcohol consumption of 55 drinks / week carries greater 
risk than tobacco alone. 
  
U – V Radiation  
 Risk of cancer of the lower lip from exposure to UV radiation, in 
areas close to the equator. 
 Lips are at increased risk, since it lacks a pigmented layer.  
 
 
Viruses    
   HPV (6 and 16) are at increased risk for oral cavity cancer.  
 HPV 16 Æ 5 times more common risk. 
 HPV 6 Æ 3 times more common risk. 
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Diet Nutrition  
 Iron deficiency anaemia (Plummer Wilson Syndrome) (or) Paterson 
Brown – Kelly Syndrome. 
 Vitamin A, C & E deficiency. 
 
Dental Factors 
 Poor Oral Hygiene leads to higher levels of salivary acetaldehyde a 
Known carcinogen in oral cavity cancer.  
Persistent Irritation to the oral mucosa in the form of ill fitting dentures 
can lead to dysplastic changes in the epithelium 
 
Occupational exposure  
 Usage of certain chemicals including Formaldehyde, Nickel, Chromium 
and leather Tanning Products, are at increased risk.   
 
Immune Competence 
 Compromised Immunity related to HIV Infection, organ transplantation, 
chemotherapy (or) Radiation therapy acts as contributing factors. 
 
Genetic & Familial Syndromes  
 Syndromes associated with defective DNA repair including xeroderma 
Pigmentosa, Ataxia Telangectasia, Bloom's syndrome and Fanconis anaemia 
are at increased risk.    
 
Increased risk of second primary Malignancy of oral cancer found 
commonly in LiFraumeni syndrome (P53 deficiency) 
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PREMALIGNANT CONDITIONS 
1) Oral Leukoplakia  
 Defined as white keratotic Plaque (or) Patch. key pathological features 
include hyperkeratosis, Parakeratosis and acanthosis.   
Varieties include Leukoplakia Simplex, Leukoplakia Verrucosa, and  
Leukoplakia erosive.  
 
2) Erythroplakia 
 Red mucosal patch is more commonly found in soft palate and tonsillar 
fossa.  7 times higher risk than Homogenous Leukoplakia.  
 
3) Erythroleukoplakia  
 5 times more risk than Homogenous Leukoplakia.  
 
4) Proliferative verrucous Leukoplakia (PVL) 
Proliferative, generally irregular white patches (or) plaques that 
progress slowly multifocally in the oral mucous membrane.  100% can 
develop Squamous / verrucous cell ca. 
Most patients of PVL are non smokers; women are at increased risk 
than men, peak age of incidence is between 60 and 70 yrs.  
 
5) Lichen Planus : Lymphocytic Infiltrate in epithelial layers.  
 
6) Oral sub mucosal Fibrosis  
Causative agent Areca–catecha a component of Betel-nut thought to 
affect collagen synthesis. It presents with thickened, White mucosa lacking 
elasticity. 
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7) Sublingual keratosis  
 
8) Oral epithelial Dysplasia :  Epithelial dysplasia characterized clinically by 
an alteration in oral epithelium.  
 
Other premalignant lesions  
 Actinic keratosis  
 Discoid Lupus Erythematosis  
 Chronic Hyperplastic conditions 
 Atypia in Immunosuppression  
  Syphilitic Leukoplakia.  
 
Treatment of Premalignant Conditions 
 Biopsy shows no malignant transformation – observation of the 
patient  
 Larger area shows extensive lesion – Excision of mucosa and 
grafting. 
 Cryotherapy, CO2 laser ablation, Low dose β carotenes, Topical 
steroids, Topical cyclosporine and Retinoids are used for treating 
premalignant conditions.  
 
CLASSIFICATION OF TUMORS 
1) Primary 
2) Secondary  
 
Primary Epithelial Origin  
- Squamous Cell Carcinoma 
- Adeno Carcinoma 
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Non Epithelial Origin  
 Melanoma, soft tissue sarcoma, Plasmacytomas 
 
Squamous Cell Carcinoma and Other Variants Include  
- Lymphoepithelioma, 
- Spindle cell Carcinoma  
- Verrucous – Papillary (exophytic) 
– Adenoid (Acantholytic) 
– Adeno Squamous  
– Baseloid 
– Undifferentiated carcinoma  
– Transitional cell carcinoma 
– Keratinized Carcinoma  
– Non Keratinized Carcinoma.  
 
Adenocarcinoma and their variants  
- Malignant Mixed Carcinoma 
- Adenocystic Carcinoma 
- Mucoepidermoid Carcinoma  
- Acinic cell carcinoma.  
 
 
PATHOLOGY  
 Majority of Head and Neck Cancers arise from the surface epithelium 
therefore squamous cell Cancer and its variants, are the most common type.  
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MECHANISM OF CARCINOGENESIS 
 
 
 
Normal Oral                
Mucosal Cell  
 
 
 
 
Verrucous carcinoma 
Verrucous is a Low grade Squamous Cell Carcinoma found most often 
in the oral cavity particularly in the buccal mucosa and gingiva.  
 
Verrucous carcinoma resembles a wart with, distinct margin, 
Roughened, cobblestone appearance, it rarely develops Lymph node 
Metastasis. 
 
HISTOLOGICAL GRADING  
 Broders established a histological grading for Squamous Cell 
Carcinoma based on Microscopic evaluation of the tumor.  
 
 Cellular differentiation based on the degree of cellular pleomorphism, 
frequency of mitoses and extent of Keratinisation.   
It is classified as  
a) Well differentiated (Grade – I) 
b) Moderately differentiated (Grade II)  
c) Poorly differentiated (Grade III) 
d) undifferentiated (Grade IV) 
Smoking 
HPV 
Betel nut 
Low 
Vitamin A, 
E, C Se, 
beta 
carotene,  
folates   
Genomic Instability 
Genetic Mutations  
3p, 9p, 13q, 18q, 17p  
Aneuploidy  
Promoter Hypermethlation 
Telomerase activation  
COX-2 upregulation 
EGFR Activation 
Cyclin-D1 elevation  
Oral cavity 
squamous cell 
cancer 
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Some may Include pattern of Invasion, stage of Invasion, presence of 
angiolymphatic tumor thickness, DNA content and their Serum Markers.  
 
CHIEF SYMPTOMS   
 Ulcer     ϖ  Dysphonia  
 Swelling    ϖ  Reromolar Extension 
 Fetor     ϖ Ankyloglossia 
 Excessive salivation   ϖ  Trismus 
 Difficulty in chewing   ϖ Bony erosion 
 Lump in neck    ϖ Dysphagia  
 Pain         
       
METHODS OF SPREAD OF SQUAMOUS CELL CARCINOMA 
I. Local Spread  
II. Lymphatic  
III. Blood borne  
 
I.  LOCAL SPREAD  
a) Invasion of Soft tissues  
Infiltrate deeply into adjacent connective tissue, carcinoma tongue 
Infiltrate more posteriorly than anteriorly. 
 
b) Invasion of Perineural spaces  
Perineural spread is characteristic of adenoid cystic Carcinoma.  
Centripetal Infiltration of tumor along the branches of mandibular nerve 
(Inferior Dental, Long Buccal, or Lingual), is common.  For this reason, 
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whenever the mandible is resected, Inferior dental bundle should be resected 
as high as possible.  
 
c) Invasion of Vessels 
 Invasion of arteries are rare.  Main predisposing factors are irradiation 
of neck, necrosis of skin flap, infection and salivary fistula.  
 
 Even in patients with carotid rupture Infiltration not seen.  No 
correlation is seen between infiltration of internal jugular vein and presence of 
systemic metastasis.  
 
d) Invasion of Bones  
Principle mode of access  
1. Facial bones by direct extension.  
2. Anatomical openings such as inferior dental canal and Incisive 
palatine foramen.  
3. Periosteal lymphatic spread may occur.  
Despite the dense cortical plate, Mandibular Invasion is more common 
than Maxillary Invasion. 
 
II.   LYMPHATIC SPREAD  
 Cancers of the oral cavity mainly Involves (Level I, II & III) (Sub mental, 
Sub mandibular, upper, middle  cervical) and Jugulo digastric Nodes. 
 
Important prognostic factors include multiple involved nodes, 
metastasis in low cervical nodes, and extra capsular invasion.  
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III. BLOOD BORNE SPREAD  
 Risk of Distant metastasis is infrequent.  Poorly differentiated & 
younger patients are at more risk.  Lungs, Liver and Bone (Vertebrae, Ribs 
and Skull) are involved in blood borne spread.  
 
According to anatomical area modes of spread    
1. Lips Skin, Commissure, Mucosa and Muscle 
   
2. Gingiva Soft tissue, buccal mucosa, Periosteum, 
Bone, maxillary antrum and Dental nerves 
   
3. Buccal mucosa Side walls of the oral cavity, Lips, 
Retromolar trigone and Muscles 
   
4. Hard palate Soft palate, Bone, maxillary antrum and 
Nasal cavity 
   
5. Retromolar Trigone Buccal mucosa, Anterior pillar, Gingiva and 
Pterygoid muscle  
   
6. Floor of mouth  Soft tissue, tonsils, salivary glands, Root of 
tongue, Base of tongue and Geniohyoid-
mylohyoid muscles 
   
7. Tongue Anterior two thirds of tongue, Lateral 
borders, Base and underside of tongue and 
Floor of mouth  
 
PRETREATMENT EVALUATION 
 
Complete History & Physical Examination  
 Biopsy of the primary 
 FNAC of the neck nodes. 
 Incision / Excision biopsy of the nodes.  
 23
Imaging Studies  
 Chest X ray – PA view.  
 CT / MRI of Primary and Neck – To know the extent of primary 
and Cervical Nodal involvement. 
 Panorex (Or) dental x ray – To Evaluate mandibular invasion.  
 
Laboratory tests  
 Pre anaesthetic testing  
 Baseline Liver function tests  
 Additional laboratory tests as per the patient medical history.  
 
Examination under anaesthesia  
- Direct laryngoscopy & pharyngoscopy 
- Esophagoscopy 
- Bronchoscopy  
- Palpation of tongue, oro and Naso Pharynx.  
 
Neck Nodes  
 Histological demonstration of metastasis in a lymph node is gold 
standard.  
Investigations for neck nodes include – computerized tomography, MRI 
and FDG – PET. 
 MRI and CT have higher sensitivity & specificity than clinical 
examination in detection of metastasis.  
CT / MRI can detect lymph nodes larger than 1.5 cm in diameter.  
FDG–PET is more sensitive & specific than CT / MRI.  Current      
FDG–PET can detect tumors smaller than 1cm.  
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 CT & MRI detect the metastasis, relationship of a metastatic tumor with 
critical structures such as internal carotid artery, cervical spine, vertebral 
artery and brachial plexus.  
 
New MRI Methods  
a) Volumetric Interpolated Breath Hold Examination (VIBE) 
b) Functional imaging using Dynamic Contrast enhanced MRI.  
c) Diffusion weighed Imaging. 
d) Iron oxide enhanced MRI. (Ultra small super paramagnetic Iron 
oxide) USPIO.  
Above techniques may have a role in future.  
 
TNM STAGING 
Primary Tumor (T) 
TX Primary tumor cannot be assessed  
T0 No evidence of primary tumor  
Tis  Carcinoma in situ  
T1 Tumor 2 cm or less in greatest dimension  
T2 Tumor more than 2 cm but not more than 4 cm in greatest dimension  
T3 Tumor more than 4 cm in greatest dimension 
T4  Tumor invades through cortical bone, inferior alveolar nerve, floor of 
mouth, or skin of face, (i.e.) chin or nose.  
T4a Tumor invades adjacent structures through cortical bone, into 
deep muscles of tongue (genio-glossus, hyoglossus, 
palatoglossus, and styloglossus), maxillary sinus and skin of 
face.  
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T4b Tumor invades masticator space, pterygoid plates, skull base or 
encases internal carotid artery.  
 
Regional Lymph Nodes (N) 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis  
N1 Metastasis in a single ipsilateral lymph node, 3 cm or less in 
greatest dimension.   
N2 Metastasis in a single ipsilateral lymph node, more than 3 cm 
but not more than 6 cm in greatest dimension; or in multiple 
ipsilateral lymph nodes, none more than 6 cm in greatest 
dimension; or in bilateral or contralateral lymph nodes, none 
more than 6 cm in greatest dimension 
N2a Metastasis in single ipsilateral lymph node more than 3 
cm but not more than 6 cm in greatest dimension.  
N2b Metastasis in multiple ipsilateral lymph nodes, none more 
than 6 cm in greatest dimension  
N2c Metastasis in bilateral or contralateral lymph nodes, none 
more than 6 cm in greatest dimension  
N3 Metastasis in a lymph node more than 6 cm in greatest 
dimension.  
 
Distant Metastasis (M) 
MX Distant metastasis cannot be assessed  
M0 No distant metastasis  
M1 Distant metastasis  
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STAGING  
Stage 0 Tis N0 M0 
Stage I T1 N0 M0 
Stage II T2 N0 M0 
Stage III T3 N0 M0 
 T1 N1 M0 
 T2 N1 M0 
 T3 N1 M0 
Stage IVA T4a N0 M0 
 T4a N1 M0 
 T1 N2 M0 
 T2 N2 M0 
 T3 N2 M0 
 T4a N2 M0 
Stage IVB Any T N3 M0 
 T4b Any N M0 
Stage IVC Any T Any N M1 
 
 
TREATMENT OF ORAL CAVITY CARCINOMA 
Treatment of oral cavity Carcinoma requires multimodality 
management.  
 
Goals  
 According to the stage of tumor, the treatment protocol varies. It is 
roughly divided into resectable disease and unresectable disease.  
“Unrescetable” refers to tumors that cannot be removed without 
unacceptable morbidity and if it involves the vital structures like cervical, 
Brachial plexus, carotid artery it can be termed unresectable.  
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SURGERY  
a) Surgery of the primary alone 
b) Surgery of the primary with mandibulectomy  
c) Surgery of the primary with neck dissection.     
d) Surgery of the primary with neck dissection & mandibulectomy 
 
I) LIP CARCINOMA   
Enbloc removal of the tumor with 2cm clearance in all dimension.  
 
Tumors less than 2 cm   
i) Moh’s micrographic excision 
ii) Alternative forms of therapy include  
 Cryotherapy,  
 Electrocautery, 
 Chemotherapy (Topical application of 5FU) 
 Photodynamic therapy.  
Alternative forms are mainly used for tumors less than 1.5 cm.  
 
Tumors more than 2 cm   
 If carcinoma is advanced, bone and neural involvement should be ruled 
out by doing OPG (Orthopantagram) / CT / MRI of the Mandible.  
 
 If mandible is involved composite resection (Tumor removal with / 
Segmental Mandibulectomy and Neck dissection) is the surgery of choice.  
 
II) TONGUE CARCINOMAS  
 Surgical resection of the oral tongue with tumor free margin of at least 
1 cm. 
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T1T3 No  – Partial glossectomy. 
Large Cancers – Extensive surgery such as total   
glossectomy and Reconstruction. 
 
III) ORAL CAVITY EXCLUDING TONGUE & LIP 
 Resection of the floor of mouth, buccal mucosa, tongue and mandible 
can be done by any one of the four approaches.  
It includes,  
 
a) Transoral  
b) Mandible sparing (Pull through) 
c) Mandibulotomy. 
d) Composite resection. 
 
a) Transoral   
 Tumors which are smaller anterior, superficial, well circumscribed 
lesions situated in the floor of mouth, anterior 2/3 of the tongue, buccal 
mucosa and palate are removed through this approach. 
 
b) Pull through procedure  
 It is ideal for moderate sized cancers of the anterior, lateral and floor of 
the mouth without Involvement of the mandible.  If the adequate surgical 
margin is not obtained it can be combined with marginal mandibulectomy. 
 
c) Mandibulotomy  
 Posterior oral cavity and oropharynx are better approached by dividing 
the mandible lateral to midline (i.e.) Anterior to mental foramen 
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d) Composite resection 
 Tumor invades the lateral (or) anterior arch of the mandible, it needs 
full thickness resection of the mandible along with tumor and neck nodes. 
Preserving the posterior edge of ramus of mandible, coronoid and condylar 
processes will help in reconstruction. 
 
RECONSTRUCTION 
 Lip reconstruction :  Upper Lip,  
     Lower Lip, 
    Lip Commisure  
Total defect is less than 30% - Primary closure. 
If it is more than 30% - Partial / Full thickness Skin graft / Vicinity  flap (Local) 
 
Skin Graft  
 Moh’s micrographic surgery, which does not involve the vernillon  
 Can be grafted, either by partial (or) full thickness graft.  
 
Vicinity flap :  
 Labial rotation and advancement flap.  
- Abbes flap (Both upper & Lower Lip defect) 
- Double Abbes flap (75% central defects of lower lip) 
- Eslander flap (Lower Lateral Lip)   
- Gillies fan flap 
- Karapandizic (Central defect more than 80%)  
- Stepladder Flap / Staircase Flap. (Central & Lateral defect) 
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Vermillion Reconstruction  
 Small defect  - Full thickness Horizontal releasing Incision.  
 Extreme vermillion  Musculo–Mucosal flap eg. Fascial artery  
Defect     Musculo Mucosal Flap.  
 
Tongue Reconstruction 
 For smaller defects  - Primary closure (or) 
Skin graft either partial (or) full thickness 
with bolstering sutures 
 For Larger defects - Pectoralis Major Myocutaneous flap  
(PMMF) for total glossectomy.  
 
Reconstruction of oral cavity excluding lip, Tongue Ca  
For Cheek  - Local flaps such as Rhomboid flap  
[Limberg  (or) Dufourmental flap] 
‘V – Y’ Local transposition flap.  
 
Musculo Cutaneous flap  
Sternocledomastoid flap  – Augment mandibular coverage  
 
Lateral & Inferior Trapezius  – Intra oral reconstruction. 
musulocutaneous flap    
 
Pectoralis Major Flap   – Total glossectomy and Composite  
post mandibular defects.  
 
Platysma flap    – Buccal sulcus and buccal mucosa.  
 
Free Flap 
 Radial Forearm flap  – oral lining restoration.  
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 Rectus abdominis flap  –  Total / Subtotal glossectomy  
(RAF)  Hemimandibulectomy and complex 
Intra-oral defects.  
 Lateral thigh flap   – Lining of oral cavity.  
 
Recipient site complications  
a) Flap necrosis  
b) Infection  
c) Fistula  
Donor site Complications  
a) Haematoma and Seroma  
b) Infection and wound dehiscence  
c) Partial / Total skin graft loss  
d) Tendon exposure  
e) Hernia and contour abnormality. 
 
BONY INVOLVEMENT 
 For mandibular invasion  
a) Marginal Mandibulectomy  
 If there is microscopic invasion of the mandible i.e. periosteum (or) 
cortical layers and for adequate access during the surgery marginal 
mandibulectomy is performed.   
 
b) Segmental Mandibulectomy  
 If there is cortical Invasion of the Mandible detected clinically, 
radiographically, (or) intraoperatively an enbloc segmental Mandibulectomy is 
done.  
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c) Partial Mandibulectomy 
 Mandible and tumor are usually resected from the mental Foramen to 
the coronoid process generally leaving behind the condyle.  
 
d) Hemi Mandibulectomy  
 Removal of the mandible-from symphysis to the condyle on one side.  
 
 
RECONSTRUCTION OF MANDIBLE 
 Mandibular resection produces major cosmetic and functional loss and 
reconstruction is by Biological & Non Biological prosthesis.  
 
Osteomyocutaneus flap  
 Trapezius flap with spine of scapula  
 Pectoralis Major flap with 5th (or) 6th rib.  
 
Non Biological Prosthesis  
a) Plastics : Acrylic, Teflon, Slapstick  
b) Inert Metals : Stainless steel, Tantalum, Vitallium and Titanium.  
 
Biological Prosthesis 
 Bone graft, Pedicled graft, Free Flaps.  
 
 
NECK DISSECTION  
 Neck dissections are classified as follows  
 IN 1991   IN 2001 
     
1. Radical Neck dissection   1. Radical Neck dissection  
     
2. Modified Radical neck dissection   2. Modified Radical neck 
dissection  
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3. Selective Neck dissection   3. Selective Neck dissection  
     
 a. Supraomohyoid    a. SND (I-III / IV) 
 b. Lateral     b. SND (II-IV) 
 c. Posterolateral    c. SND (II-V, Post auricular, 
Sub occipital) 
 d. Anterior    d. SND (Level VI). 
     
4. Extended Neck dissection  4. Extended Neck dissection 
 
Various incisions are being used for neck dissection (a) Latyschevsky                   
(b) Freund (c) Crile (d) Martin (e) Babcock and conley. 
 
1)  Radical Neck Dissection  
Removal of level I-VI nodes along with removal of Internal Jugular 
Vein, Spinal Accessory Nerve and Sternocledomastoid Muscle. 
 
2)  Modified Neck Dissection  
Removal of Level I-VI Nodes along with preservation of Internal jugular 
vein, Sternocledo mastoid muscle, and Spinal accessory nerve 
Type – I  : Preserves only Spinal Accessory Nerve.  
Type – II : Preserves Internal Jugular. Vein & Spinal Accessory Nerve 
Type – III : Preserves Sternocledomastoid, Internal Jugular Vein and  
       Spinal Accessory Nerve. 
3) Selective Neck Dissection 
a) Supraomohyoid Neck Dissection: (SND-I-III) 
 Removal of Level I-III nodes. 
b) Extended Supraomohyoid Neck Dissection : (SND-I-IV) 
  Removal of Level I-IV nodes. 
 
c) Lateral Neck Dissection (SND II – V) 
 Removal of II-IV nodes along with Internal Jugular Vein 
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d) Posterolateral Neck Dissection : (SND II – V) 
Removal of II – V group of nodes. 
 
e) Anterior Neck Dissection: (SND VI) 
Removal of Level VI nodes. 
 
4.  Extended Neck Dissection 
 Neck dissections can be extended to include either of the Lymph node 
groups that are not routinely removed i.e. Retropharyngeal, Paratracheal, 
Upper mediastinal (or) other structures such as skin of the neck, carotid 
Artery, Levator Scapula, Vagus (or) Hypoglossal nerve. 
 
SURGERY FOR N0 NECK  
 Clinical examination, imaging and pathological assessment fail to 
detect any evidence of regional disease it is called as N0 Neck. 
 
Treatment options for No Neck 
a) Elective Neck Dissection 
b) Elective Neck Irradiation 
c) Sentinel lymph node Biopsy 
 
Elective Neck Dissection   
 When the primary tumor is treated with surgery, elective neck 
dissection is preferred. 
 
Elective Neck Irradiation 
 When primary tumor is treated with radiotherapy, elective neck 
irradiation is preferred.  
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Sentinel Lymph node Biopsy 
 Newer option for staging the Neck.  Lymphatic drainage from a primary 
tumor is limited to set of regional lymph nodes, which are identified by 
contrast agents (or) radioactive tracers, those identified nodes are removed. 
 
SURGERY FOR NODAL DISEASE 
N1, N2, N3      - Neck dissection (Modified Radical Neck dissection 
/ Radical Neck dissection / Selective Neck 
Dissection) and Post Operative Radiotherapy 
optional if, extracapsular involvement of the nodes 
are present.  
Surgery for Bilateral Nodal disease   
 Bilateral neck dissection simultaneously with preservation of one of the 
Internal jugular vein. 
 
Surgery for Metastatic disease 
 Retropharyngeal, Internal jugular vein and Posterior triangle nodes are 
involved, radiotherapy is the best option.  It is a bad prognostic indicator. 
 
Complications of Block dissection Emergency Complications 
    
a. Infection (1.7%) a. Carotid Artery rupture 
    
b. Air Leak b. Jugular Vein Blow out 
    
c. Bleeding   
    
d. Chylous Fistula    
    
e. Fascial or cerebral edema   
    
f. Blindness   
    
g. Apnoea   
    
h. Jugular Vein Thrombosis   
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Radiotherapy for Nodal Involvement  
 Primary Radiotherapy for the Nodes, several important factors are 
taken into account.  
a) Nodal size 
b) Nodal Number 
c) Nodal fixation 
d) Duration of Radiation 
 
RADIATION THERAPY 
 Main stay of treatment for cancer in the head and neck region. 
 
Choice of therapy 
a) External Beam Therapy 
b) Brachy Therapy 
c) Intra Operative Radiation Therapy 
 
RADIOTHERAPY FOR CANCER OF THE LIP 
 
Definitive RT  Primary  
 External beam RT > 66 Gy (2.0 Cy / day) 
 External beam RT > 50 Gy+ brachytherapy  
 Brachytherapy alone  
Neck  
 > 50 Gy (2.0 Gy/day) 
  
Adjuvant RT  Primary 
 External beam RT > 60 Gy (2.0 Gy/day) 
Neck 
 50 – 60Gy (2.0 Gy/day) 
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RADIOTHERAPY FOR CANCER OF THE ORAL CAVITY  
 
Definitive RT  Primary  
 External beam RT > 70 Gy (2.0 Cy / day) 
 External beam RT > 50 Gy+ brachytherapy  
 Brachytherapy alone  
Neck  
 > 50 Gy (2.0 Gy/day) 
  
Adjuvant RT  Primary  
 External beam RT > 60 Gy (2.0 Gy/day) 
Neck 
 50 – 60Gy (2.0 Gy/day) 
 
 
a) External Beam Radio Therapy (Teletherapy) 
Dual energy linear accelerators capable of generating 
i) Low energy megavoltage (4-6 mv) 
ii) High energy megavoltage (15-25mv) 
iii) Range of electrons (6-18 to 25 mv) 
 
Head and neck cancers are better managed with 4-6 mv Cobalt-60 rays, with 
depth not more than 7-8 Cm. 
 
Intermittent daily dose is given for 5 days in a week for a period of             
7-8 weeks, neighboring normal tissues also get its share of dose and damage 
may occur. 
 
Conformal Radiotherapy  
High dose of radiation to the target volume and small dose to normal 
tissues. 
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IMRT (Intensity Modulated Radiotherapy)  
Treatment is divided into hundreds of pencil beam each one 
contributing radiation to different parts of target volume.  Computer controls 
the amount of radiation. 
 
c)  Brachy-Therapy 
 Selectively used in Treatment for early T1 & T2 lesions and achieves 
high control rates.   
 High doses to the target volume and simultaneous sparing of normal 
areas. 
 Implants today in use are Ir-192 (or) I2-125, others are Radium 226, 
Gold-198, and Palladium-103. 
 Various techniques are used to place radioactive material in a desired 
geometric pattern.  “Paris System” is most widely used. 
 
d) Intra-operative Radiation 
 Either by electron beams or Orthovoltage Radiation.  Mainly used for 
small superficial tumors (2 – 5 Cms) preferably on flat surface. 
 
Pre-Operative Radiotherapy :  It is a debate for many years. 
 
Post Operative Radiotherapy : It is ideal in most situations. 
 Surgical margins at the primary site are positive or macroscopic 
residual disease is present.    
 Skin, Soft tissue, Cartilage and bone are involved. 
 Lymph node of Neck is histologically positive.   
 Advanced primary T3, T4 lesions. 
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Radiotherapy is usually started 4-6 weeks after surgery.  Any delay after 8 
Weeks is not ideal. 
 
Advantages of Pre-Operative RT 
 Inoperable lesion may be converted to operable 
 Extent of surgery  
 Distant metastasis may decrease. 
 
Disadvantage of Pre-Operative RT 
 Increased morbidity 
 Decreased wound healing. 
 
Advantages of Post-Operative RT 
 Extent of disease is known 
 Higher doses may be delivered 
 Healing is superior  
 
Disadvantages of Post-Operative RT 
 Distant metastasis likely to be greater. 
 Decreased vascularity at the time of radiotherapy due to surgical 
tampering. 
 
Pre-Irradiation Dental Care 
1) Instructions regarding the complete oro-dental hygiene, regular mouth 
wash, cleaning of mouth after each meal. 
2) Avoid hard tooth brush. 
3) Fluoride tooth paste to prevent caries. 
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4) Extraction has to be done, with a minimum of 2-3 weeks before starting 
radiotherapy. 
Post Irradiation Dental Care  
Extraction has to be carried out 18-24 months after radiotherapy once 
oral mucosa has healed. 
Recommended Skin Care  
• Wash the skin with lukewarm water, pat dry, and do not wash off marks.  
• Use mild soaps   
• Use water-based lotions or creams  
• Avoid lotions with perfume and deodorants.  
• Avoid direct sunlight.  
• Do not use straight razors. 
• Avoid tight-fitting collars  
• Do not use aftershave lotions or perfumes.  
• Apply only nonadherent, hydrophilic dressings to wounds.  
 
Complications of RT 
 Acute &  chronic 
 Dose related 
Acute:  Mucositis, dermatitis, hair loss, loss of taste, xerostomia, cataract.  
Chronic:  Soft tissue fibrosis (necrosis), Radio necrotic ulcer and Osteo radio 
necrosis. 
Dose related  
Around 20–30GY  :  Mucositis, ulceration, erythema, hyperpigmentation. 
Around 50 GY  : Dryness of mouth (Serous secretion low) 
Around 65 GY  : Severe ulceration. 
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RADIOSENSITISERS 
Chemical compounds when combined with radiation should achieve 
greater tumor inactivation than would have been expected from the additive 
effect of each modality. 
e.g.: Nitroimidazole compounds (Misonidazole – 2nd generation)  
 3rd generation (Etanidazole, Pimonidazole) 
 
RADIOPROTECTORS 
Chemical compounds that protect against radiation damage to target 
normal cells and not to tumor cells. 
e.g.: Amifostine (WR-2721), Ethyol. 
Information regarding radiosensitisers and radioprotectors will be 
available in near future. 
 
 For early lesions (T1 – T3) local cure is achieved by surgery or Radio 
therapy alone. 
 For (T3 – T4) lesions combined modality of Treatment, surgery is 
effective in removing large bulky lesion and irradiation for microscopic 
disease. 
CHEMOTHERAPY 
 Introduction of more active chemotherapeutic agents and combinations 
being increasingly used in complex multimodal treatment plans along with 
surgery and Radiotherapy. 
 
General Strategies 
1. Induction is given before surgery or radiation (Neoadjuvant 
chemotherapy) 
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2. Concomitant chemoradiation – chemotherapy is given simultaneously 
with radiation. 
3. Adjuvant therapy where chemotherapy is given after surgery (or) 
radiotherapy in an effort to reduce metastatic burden. 
Induction Chemotherapy 
 Cisplatin (100mg/m2) followed by 5 days infusion of 5FU(1gm/m2/day) 
are given before surgery.  Recently Docetaxel is added to the above regimen. 
Concomitant Radiotherapy and Chemotherapy 
 High risk patients, disease recurrence after surgical excision, multiple 
nodal metastasis and extracapsular spread are present, Concomitant   
chemotherapy and radiotherapy showed better response. 
Adjuvant Chemotherapy  
 After primary surgery or after primary radiotherapy cisplatin and 5FU 
are given.   
Intra Arterial Chemotherapy 
 Intra Arterial infusion of 5 FU bypasses the catabolic effects of liver, 
thereby prolonging the therapeutic action of drugs.  It is useful in maxillary 
sinus carcinoma. 
Immunological agents & Newer Drugs 
 Epidermal growth factor receptor (EGFR) is over expressed in invasive 
squamous cell carcinoma. 
 Gefitinib and erlotinib – single agent activity with advanced 
disease. 
 Cetuximab – murine monoclonal Antibody directed against 
extracellular domain of EGFR.   Above agents are under trial. 
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FOLLOWUP 
American Head and Neck society guidelines for cancer surveillance. 
 
Years Post Rx Follow-up 
1st Year 1 – 3 M 
2nd Year 2 – 4 M 
3rd Year 3 – 6 M 
4th & 5th Year 4 – 6 M 
After 5th Year Every 12 M 
 
 
 
CHEMOPREVENTION 
Patients with oral Intraepithelial Neoplasia have an increased risk of 
developing squamous cell carcinoma because of combination of carcinogens 
and genetic predisposition. 
 
Loss of Heterozygosity, Aneuploidy, Telomerane activation, cyclin D1 
elevation, COX-2 up regulation , EGFR activation, are all incriminated in the 
causative factors for transformation of Oral Intraeptithelial Neoplasia to 
Squamous cell carcinoma. 
 
Vitamins (A, E, C), Retinoids, Beta Carotene, Minerals, Folates and 
Selenium are agents, which probably prevent the transformation of Oral 
intraepithelial Neoplasia to oral cavity Carcinoma. 
 
FUTURE DIRECTIONS 
Nanotechnology  
 Magnetic properties of hydrogen in biologic tissue is one of the 
most powerful diagnostic tools in medicine. It  is used in Nano-
technology   
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 Cells Irradiated with Nanoshells causes circular zones of cell 
death.  Nanoshells mediated Infrared therapy are used for 
tumors under magnetic resonance.  
 
Personalized therapy  
 Microarray C-DNA library analysis allows measurement of 
expressions of tens of thousands of genes by cancer cells.  
 In near future a treatment programme of 10 (or) even 100 
monoclonal antibody based agents as determined by micro 
array analysis will be available.  
 
SCREENING FOR ORAL CANCERS 
 Four methods are available for early cancer detection.  
- Visual examination  
- Application of toluidine blue  
- Self screening  
- Oral cytology 
 
1. Visual examination  
 Sensitivity for oral visual examination 58% - 94% 
 Specificity rate for oral visual examination 76% - 98% 
 
2. Application of toludine blue : 
Application of toludine blue will provide demarcation between 
malignant and dysplastic cells.   It will be useful in the early detection of oral 
cancers in selected subjects with precancerous lesions.   
 
False negative and false positive rates range from 20-30% 
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3. Self Screening  
 In High risk population groups self screening is mandatory and 
flexibility depends on health education.  
 
4. Oral cytology  
 Oral exfoliative cytology, a screening modality has major limitation. 
There is a high false negative rates hence biopsy is preferable than oral 
cytology. 
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MATERIALS AND METHODS  
 The clinical material for this study consists of 140 patients of oral cavity 
cancers out of 427 patients who attended Thanjavur Medical College Hospital 
(2005-2007). 
287 were not included in the study, because of failure of follow up and 
irregular treatment.   
 The patients age, sex, Habits, socio economic status, premalignant 
conditions, clinical features, site of oral cavity, staging, histopathology were 
recorded.  
 
Following Investigations were taken up for Diagnostic and staging 
purpose,  
1) HPE   2) X-ray Mandible AP / Lateral   
3) X-rays PNS  4) X-ray Chest-PA view   
5) USG Abdomen 6) CT Fascial Bones  
 
For Clinical assessment and for co morbid conditions  
i) Urine – Albumin & Sugar   
ii) Blood Hb%  
iii) Renal parameters  - Blood sugar, urea and serum creatinine  
iv) Serum. electrolytes     
v) Liver function tests   
vi) Complete Haemogram    
vii) Clotting Time & Bleeding Time   
viii) ECG in all chest leads were taken.  
Dental surgeon’s opinion and help were obtained in selected cases.   
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Treatment protocol  
Planned accordingly  
1) External Beam radiotherapy 
2) Surgery  
a. Primary surgery alone  
b. Primary Surgery with neck dissection  
c. Primary Surgery with Mandibulectomy  
d. Primary Surgery with neck dissection and Mandibulectomy  
 
Primary reconstruction was done.  
Immediate post operative complications were identified and treated.  
 
In the follow up, patients were observed regarding the local recurrence 
nodal disease (or) recurrence in neck treated and evidence of Second primary 
with (or) without metastasis.  
 
The patients were informed regarding the risk factors and advised to 
give up the offending Habits to have longer disease free survival.  
 
The relatives were cautioned regarding the correlation between risk 
factors and oral cavity carcinoma.  
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OBSERVATION AND RESULTS 
 
 
INCIDENCE OF ORAL CANCER IN THANJAVUR MEDICAL COLLEGE 
HOSPITAL  
 
Year Total cases of Malignancy 
Total cases of 
oral cancer 
% of oral 
cancers 
June – Dec. 2005 709 96 13.5% 
2006 1641 211 12.8% 
Jan – Sep. 2007 1130 120 10.6% 
 3480 427 12.2% 
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Fig – 3 - Oral Cavity Cancers constitute 12.2% of the total malignancy 
reported in Thanjavur Medical College Hospital.  
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INCIDENCE OF ORAL CANCER ACCORDING TO ANATOMICAL AREA   
Sl. 
No. Cancer Site 
Total No of 
Cases % 
1. Cheek 72 51.4 
2. Tongue 36 25.7 
3. Lips 11 7.9 
4. Alveolar Ridge 9 6.5 
5. Floor of Mouth 6 4.3 
6. Hard Palate 5 3.5 
7. Retromolar Trigone 1 0.7 
 Total 140  
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Fig – 4 - Cheek was the most common site of oral cancer reported in 51.4% 
and Tongue was the next common site (25.7%). 
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DISTRIBUTION OF PATIENTS IN VARIOUS AGE AND SEX GROUPS  
 
Male Female Total 
Age (Year) 
No. % No. % No. % 
31-40 12 12.1% 6 14.6% 18 12.8% 
41-50 41 41.4% 13 31.7% 54 38.6% 
51-60 29 29.3% 12 29.3% 41 29.3% 
61-70 10 10.1% 6 14.6% 16 11.4% 
>71 7 7.1% 4 9.8% 11 7.9% 
Total 99  41  140  
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Fig – 5 - Both males and females peak age of incidence is 40 to 50 years.  
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OCCUPATION WISE INCIDENCE OF ORAL CANCER 
 
Groups Socio-economic status 
Number of 
Patients % 
I Low 129 92.14% 
II Moderate 11 7.86% 
III High - - 
  140  
 
 
 
 
0.00%
20.00%
40.00%
60.00%
80.00%
100.00%
%
 o
f P
at
ie
nt
s
Low Moderate High
Socioeconomic Status
OCCUPATION WISE INCIDENCE OF ORAL 
CAVITY CANCER
 
Fig – 6 – oral cancer was commonly found in low socio economic status             
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Sl. 
No.  Factors  Total No.  % 
Chewing Betel nut + Tobacco 86 
1. 
Chewing Tobacco  32 
84.2% 
2. Smoking  77 55% 
3. Alcoholism  44 31.4% 
4. Dental Caries & Dental lesions 14 10.0% 
5. Nutritional deficiency  2 1.7% 
6. None  12  8.6% 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig – 7 - Chewing tobacco, slaked lime and betel nut was the most common 
risk factor.   
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MODES OF PRESENTATION OF ORAL CAVITY CANCER 
 
Clinical Features Cheek Carcinoma 
Tongue 
Carcinoma 
Lip 
Carcinoma 
Alveolar 
Carcinoma 
Hard Plate 
Carcinoma 
Floor of 
mouth 
Carcinoma 
Total 
Ulcer 72 36 11 9 5 6 139
Swelling 31 5 8 5 2 4 55 
Lump in neck 13 7 4 3 2 2 31 
Pain 11 2 3 2 1 2 21 
Trismus 7 - - - - - 7 
Retromolar extension 5 - - - - - 5 
Other Symptoms        0 
Excessive Salivation 34 12 4 - - - 50 
Difficulty in Chewing 18 - - - - - 18 
Dysphagia - 4 - - - - 4 
Dysphonia - 4 2 - - - 6 
Ankyloglossia - 5 - - - - 5 
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Fig – 8 - Majority of the patients reported with ulcer. 
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Sl. 
No.  Factors  Total No.  % 
1. Leukoplakia  51 36.4% 
2. Submucosal Fibrosis  21 15.0% 
3. Erythroplakia  17 12.2% 
4. Leukoplakia + Erythroplakia  8 5.7% 
5. Candidiasis  5 3.6% 
6. Not associated with any lesion  38 27.1% 
 Total 140  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Fig – 9 - Leukoplakia was the most common premalignant condition 
encountered.  
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DISTRIBUTION OF PATIENTS ACCORDING TO THE TYPE OF GROWTH  
 
 
Sl. 
No.  Growth Type  
No. of 
patients  % 
1. Endophytic  83 59.3 
2. Exophytic  29 20.7 
3. Invasion of Soft tissues  19 13.6 
4. Invasion of Bone and Neurovasular bundle  9 6.4. 
 Total 140  
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Fig – 10 - Majority of the patients presented with endophytic growth.
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DISTRIBUTION OF PATIENTS ACCORDING TO HISTOLOGICAL TYPES 
 
Sl. 
No.  Factors  Total No.  % 
1. Squamous Cell Carcinoma    
 Well Differentiated 62 44.3% 
 Moderately Differentiated  49 35.0% 
 Poorly Differentiated  23 16.5% 
95.8%
2. Mucoepidermoid Carcinoma 3 2.1%
3. Adenoid Cystic Carcinoma 2 1.4%
4. Adeno Carcinoma  1 0.7%
 Total 140  
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Fig – 11 - Well differentiated Squamous cell carcinoma was the major 
histopathological type. 
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DISTRIBUTION OF PATIENTS ACCORDING TO TNM STAGING  
 
 
Sl. 
No. No. of Patients Percentage 
I 9 6.4% 
II 41 29.3% 
III 62 44.3% 
IV 28 20.0% 
Total  140  
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Fig – 12 - Majority of the patients reported to us were in Stage III and IV.
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 TREATMENT OUTCOMES IN ORAL CAVITY CANCER 
Staying Primary Surgery 
Primary Surgery 
+ 
Mandibulectomy
Primary 
Surgery + 
Neck 
dissection 
Primary surgery 
+  Neck 
dissection + 
Mandibulectomy 
Primary 
Radio 
therapy
Stage I 8    1 
Stage II 19  2  20 
Stage III  8  5 49 
Stage IV  3  3 22 
Total 27 11 2 8 92 
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Fig – 13 - Primary Radiotherapy was given to 92 patients. Most of them were 
in Stage III & IV. Primary Surgery was done for majority of patients in Stage I 
& II. 
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COMPLICATIONS ENCOUNTERED IN POST-OPERATIVE PERIOD  
Sl. 
No.  Complications No. of cases % 
1. Wound Infection  8 16.7% 
2. Fistula Formation  7 14.6% 
3. Flap Necrosis  5 10.4% 
4. No Specific Complaints 28 58.3% 
  48  
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Fig – 14 - 58.3% had no specific complaints. Remaining had wound infection, 
Flap Necrosis and Fistula Formation. 
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DISCUSSION 
 
An analysis of the incidence, predisposing factors, premalignant 
conditions, clinical features, type of growth, histological types, stage of 
presentation and treatment modalities carried out for oral cancers in our 
hospital for the period from June 2005 to September 2007 are discussed. 
 
EPIDEMIOLOGICAL ANALYSIS 
 In our institution oral cavity cancers (12.2%) constitute the 2nd most 
common cancer next to breast. 
 
 According to the National Cancer Registry Programme (NCRP) -           
ICMR Survey shows that Oral Cavity cancer occupies the most common 
carcinoma in male (19.4%), is followed by hypopharynx and esophagus.  In 
females Cervix Uterus is followed by Breast and oral cancer (38.7%). 
 
 The reference in Indian Medical Literature regarding the 
preponderance of oral cancer in India suggests its strong association with 
habit of chewing betel nut, tobacco, slacked lime and smoking habit             
(Nilbock et al.) 
 
 Cancer Institute (WIA), Chennai-statistics shows that the leading 
cancer site in male is oral cavity (9.9%) and in female Cervix Uterus (32.2%) 
among the top ten cancers (Fig – 15). 
 
In JIPMER-oral cavity forms the most common cancer in male (16.6%) 
and Cervix Uterus (55.1%) forms the most common cancer in female among 
the top ten cancers (Fig – 16). 
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 In our study the peak incidence of oral cavity cancer is between            
40 and 50 Years. 
 
 According to the National Cancer Institute SEER Programme – USA, 
the mean age of diagnosis is 65 years and more than 50% occurs above the 
age of 60 Years. 
 
The disparity in age incidence is mainly due to the early tobacco and 
betel leaf chewing habit in Indian patients reported by Shantha et al. 
 
Our study reveals that chewing tobacco and betel nut present in 
84.2%, and of them 80% have started it before the age of 25 Years.  Young 
age chewing habit and the number of years of usage are the reasons for oral 
cancer at earlier ages. 
 
Recently, it has been found out that increased incidence of oral cavity 
cancers detected at earlier ages probably due to the habit of chewing and 
smoking among the students evidenced by oral Cavity Cancer under the age 
of 35 Years (IJEY. E.M. et al., 2002). 
 
According to the centers for disease control and prevention 2002, 
U.S.A. - Tobacco usage was  increased among middle and high school 
students. 
MALE - FEMALE RATIO 
 
 Male - female ratio in this study is 2 : 1. 
 National Cancer Registry, U.S.A. - 2.2 : 1 
 Aringnar Anna Cancer Institute, Kanchipuram – 2 : 1  
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It is believed that preferential sex incidence is due to the greater use of 
tobacco, betel nut and alcohol by men than women. 
 Female cases were reported higher in Greece (Zavras A.I., et al. 
2003).  
 Snuff dripping and increased incidence of oral cancer among women in 
Southern United States (Win. D.M., et al) 
 
SOCIO-ECONOMIC STATUS 
 In our study majority of patients with oral cancers (92.14%) are from 
low socio-economic status. 
 
The reasons may be due to multiple factors like  
a) Poor Nutritional Status. 
b) Bad oral hygiene. 
c) Social customs. 
d) Addiction to tobacco, Betel leaf and alcohol. 
e) Lack of health awareness. 
 
ETIOLOGICAL FACTORS 
 Major etiological factor is chewing tobacco in more than a decade 
either continuously (or) intermittently. 
 No. of Patients  Duration of addition in yrs. 
12  12.4%  > 5 
39  39.7%  > 10 
28  28.5%  > 15 
19  19.4%  > 25 
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Information from the patients regarding the duration of addiction for 
chewing shows that about 87.6% of patients have been chewing tobacco for 
more than a decade either continuously (or) Intermittently. 
 
Tobaccos which is smoked as beedi, cigarette (or) pipe has been found 
in 55% of patients.    
 
In our study alcohol usage is found in 31.4%.   Alcohol has been 
incriminated as one of the causes for oral cancer.  
 
Alcohol has indirect role.  Almost all heavy drinkers are also heavy 
smokers.  Alcohol in turn increases the absorption of tobacco and increases 
nutritional deficiency.   These factors make squamous cells more susceptible 
for conversion into cancer cells.  
 
 Alcohol is the primary risk factor as suggested by “Mash berg et al. - 
USA. 
 
 Dental lesions such as sharp tooth and artificial denture produce 
constant trauma in 10.0% of the individuals has been associated with 
Carcinoma of Buccal mucosa.  
 
 Role of poor Nutrition in oral cancer has been thought as a significant 
factor.  B-Complex deficiency and sideropenia have been observed in Oral 
Cancer patients.  In our study signs of Chronic Nutritional deficiency like 
angular chelitis, atrophic tongue and glossitis are observed in 1.7%. 
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ANATOMICAL LOCATION 
In our study Buccal mucosa – constitutes 51.4% of oral cavity cancer.   
Increased incidence of buccal mucosa carcinoma is also found in 
Aringar Anna Cancer Institute, Kancheepuram. 
Tongue is the most common site (25.7%), next to buccal mucosa,. 
 Disparity in this involvement is mainly due to the habitual tobacco and 
betal chewers to keep the Quid in bucco gingival sulcus.  
 
 Reverse smoking (Chutta inside the mouth) is associated with cancer 
of the palate found in Andhra Pradesh.  
 
 Next to tongue, Lip occupies about 7.9% in our study.   Lower Lip 
exposure to radiation is more when compared to upper lip is the reason for 
higher incidence of Lower lip cancer than upper lip.  
 
CLINICAL FEATURES 
 
 Out of 140 patients majority of them reported with ulcer or ulcero 
proliferative growth in the mouth.  
 
 Tumors of the oral cavity often ulcerate; this is probably due to friction 
of the mucous membrane during eating and partly due to Infection.  
 
 Initially the lesions are painless, but once disease advances patients 
reported with pain.  
 
Other symptoms such as excessive salivation, difficulty in chewing, 
dysphonia, dysphagia and ankyloglossia are present.  Trismus is a bad        
sign as it signifies extensive infiltration by an endophytic lesion. Patients with 
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advanced lesions reported with fungating growth, orocutaneous fistula and 
with extensive Jaw destruction. 
 
PREMALIGNANT LESIONS 
 Premalignant lesions account for 95% of oral cancers.  In our study 
majority of the patients had Leukoplakia (36.4%) followed by Submucosal 
fibrosis (15.0%), Erythroplakia, Combined Erythro Leukoplakia and 
Candidiasis. 
 
Oral submucosal fibrosis is due to a component of areca-catcha in 
Betelnet which affects the collagen synthesis.  It has been predominantly 
found in East India, Srilanka and South East Asia. 
 
 Pindborg and Colleagues suggested approximately 6% of all 
Leukoplakias become malignant.  
 
“Sugar and Baconcyz” suggested that  
31% of the lesions will disappear  
30% - Improved  
25% - Experienced no change 
 
Æ Exfoliative cytology of oral lesions has not proved to be helpful as 
majority are mostly Hyperkeratotic. 
 
HISTOPATHOLOGICAL VARIETY 
 In our study, Squamous cell (95.8%) carcinoma is the most common 
histological variety followed by Muco epidemoid, Adenoid cystic & Adeno 
carcinoma.   
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National Cancer Data Base USA reveals  
Squamous - 86.3% 
 Adeno  - 5.9% 
 Verrucous  - 2.0% 
 Kaposis  - 1.5% 
 
Out of the squamous cell carcinoma reported in our study 46.3% are 
well differentiated, 36.6% are moderately differentiated, and 17.1% are poorly 
differentiated.  
 
In a study by Khanna et al shows that 58% are well differentiated, 32% 
are moderately differentiated and 10% are poorly differentiated. 
 
Multilentric origin of oral Squamous cell carcinoma - Slaughter DP et al.  
We do not encounter such cases in our study.  
 
TYPE OF GROWTH 
 59.3% of the patients had Endophytic growth, 20.7% with exophytic 
growth and 20.0% presented with invasion of the adjoining soft tissues and 
bone.  
 
STAGING  
 
In our study about 35.7% presented with N0 neck (Stage I & II)  
64.3% presented to us with N1, N2, N3 Neck (Stage III & IV) 
Compared to the study of M.D. Anderson Cancer Centre   
 72% Patients presented with No neck  
 28% Patients presented with N1, N2, N3 Neck 
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National Cancer Data Base USA 
 55% Patients presented with No neck  
 35% Patients presented with N1, N2, N3 Neck 
 
 Even though oral cancers are easily accessible for physical 
examination and biopsy, majority presented to us in later stages. 
 
The reasons derived from this study are,  
 Majority of them are initially reviewed by general practioners and 
dentists and diagnosed as apthous ulcer and fungal infections, treated 
with antibiotics, antifungal agents and mouth washes and referred to 
higher centers at later stages.  
 Oral Cancer ulcers are painless to start with, by the time patient 
presented with pain the stage of the disease advances.  
 Some people are elderly and frail so there is delay in effort to visit the 
dentist (or) doctor.   
 
Distant metastasis is observed in 7.5% oral cancers by merino et al.  
 
We did not encounter a single case with distant Metastasis (IV C), 
probably, secondaries will start manifesting after adequate local treatment and 
long term follow up.  The mean follow up period in our study is short.  
 
 Majority presented with submental, sub mandibular and upper deep 
cervical nodes (I, II). 
 
 Facial nodes are present in 2 cases.  
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 Glandular metastasis is present probably due to active lymphatic 
system (pack and Ariel et. al). This system undergoes atrophy and 
degeneration with age.  
 
 Majority of patients with Nodal metastasis are between 45 and 55 Yrs. 
of age.  
 
MANAGEMENT OF ORAL CAVITY CANCER 
 
 Out of 140 patients  
 48 patients underwent surgery. 
 Remaining 92 had Radiotherapy. 
 
The main reasons for this low percentage of patients who underwent surgery 
are.  
¾ Majority of our patients at the time of presentation were clinically 
inoperable (Late presentation). 
¾ Some patients were not willing to accept the option of major surgical 
procedure.  
¾ Poor Nutritional status / Advanced disease of the patients preclude 
surgical option.  
¾ Some patients had co-morbid conditions and anaesthetically not fit for 
major surgical procedure and reconstruction  
¾ In advanced lesions treated with surgery alone has got higher 
recurrence rate, poor outcome, hence surgery not advised.  
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SURGICAL PROCEDURES CLASSIFIED INTO 4 GROUPS 
1. Surgery of the primary tumor  
2. Surgery of the primary tumor with Mandibulectomy  
3. Surgery of the primary tumor with Elective Neck dissection. 
4. Surgery of the primary tumor with neck dissection with 
Mandibulectomy (Composite resection). 
 
GROUP I  
 About 27 patients reported in stage I & Stage II, disease without Nodal 
Involvement / Mandibular Involvement are subjected to wide excision with 
tumor free Margin of 1 cm all around and depth of 0.5 cm.  
 3 dimensional soft tissue clearance accompanied by primary closure / 
partial / full thickness skin graft / Locally advanced flap – Fan flap  (Gillies) 
Gate flap, Abbes flap are done.  
 
GROUP II   
 About 11 patients in stage III & IV reported with mandibular 
involvement & neck nodes are treated with tumor clearance and Hemi 
Mandibulectomy.   
 
Reconstruction with  
1. Pectoralis major osteomyocutaneous flap with 5th rib.  for lining & cover 
with either delto pectoral flap or forehead flap   
2. Free 5th rib for mandible, pectoralis major myocutaneous flap for lining and 
cover with either delto pectoral flap or forehead flap 
3. Forehead flap for both lining and cover for smaller lesions. 
4. Bipaddle pectoralis major myocutaneous flap for both lining and cover.  
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In the above situations mandibular defect closed with wiring.  
  
For Nodal disease primary RT are given, because of co-morbid Illness 
neck dissection cannot be done.  
 
GROUP III  
2 patients in stage II (No disease) had tumor clearance along with 
elective neck dissection.  
 
GROUP IV  
About 8 patients in stage III & IV (N1, N2) disease had either 
supraomohyoid Neck dissection (5 patients) (or) composite resection (3 
patients) and reconstruction with pectoralis major myocutaneous flap for lining 
and cover with either delto pectoral or forehead flap.  
 
 Some cases of neck dissections had pre-operative elective 
tracheostomy. 
RADIOTHERAPY 
 Radiotherapy is given in 2 forms either primary radiotherapy (or) 
Adjuvant radiotherapy.  
In our study primary radiotherapy is given to majority of the patients in 
stage III & Stage IV.     
In our institution external beam radiotherapy is given to the primary 
tumor area and to the neck in 6000 cGy for 6 weeks with 200 cGy per day for 
5 days in a week.   
Advancement in the radiotherapy in the form hyper fraction RT / IMRT 
(Intensity modulated radiotherapy) are available in Regional cancer centers.  
 71
 Adjuvant RT to the primary and Neck were given to 8 patients, those 
who had positive margins and doubtful clearance during surgery.  
 
COMPLICATIONS 
 Out of 48 patients, 8 patients had wound infection, 7 developed 
orocutaneous fistula and 5 patients had flap necrosis.  
  
 28 patients had no specific complaints.  Wound infection treated with 
higher antibiotics.  Necrosed area excised and skin graft applied.  
 
FOLLOW UP 
 Follow up was advised at monthly intervals for 1st year and once in 3 
months for the 2nd year.  
  
 During the follow up period local recurrence, Nodal recurrence and 
specific complaints were recorded.   Out of 92 patients subjected to primary 
RT, 2 patients developed Nodal recurrence they were treated with Neck 
dissection and 1 developed local recurrence treated with surgical resection.  
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SUMMARY 
• Oral cancer constitutes about 12.2% of total cancers reported in 
Thanjavur Medical College Hospital.  
• Buccal mucosa was the most common site of oral cavity cancer 
(51.4%) with Tongue being the second most common site (25.7%). 
• Peak age of incidence is 40 – 50 yrs. 
• Male to Female ratio 2 : 1. 
• Habit of Betel leaf, tobacco with slaked lime were the most common 
etiological factor.  
• Low socio economic status more prone for oral cavity cancer. 
• Majority had  endophytic lesion (65.7%)  
• Ulcer was the Chief complaint among the people who presented with 
oral cavity cancer.  
• 95.8% of oral cancers were Squamous cell origin  
• 64.3% of Patients reported in advanced stages (Stage III, IVa, IVb)   
• No recorded case of distant metastasis (Stage IV-C) 
• Out of 140 patients, 48 patients underwent surgery with primary 
reconstruction and 8 of them were given adjuvant radiotherapy.    
• Post operative complications noted in 30.8%  
• No post operative mortality encountered 
• 92 patients were given primary radiotherapy in the form of external 
beam radiotherapy to tumor and neck.  
• Among the above said 92 patients, 2 patients had nodal recurrence, 
they were treated with neck dissection, 1 patient developed local 
recurrence he was treated with surgical resection. 
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CONCLUSION  
 
Oral Cancer is a national problem.   
 
Oral Cancer remains a challenge as majority of the patients reported 
are in advanced stage.  
 
Moh’s micrographic excision and alternative forms of therapy such as 
Cryo, Electro, Chemo & Photo dynamic therapy for smaller lesions and wide 
excision along with advanced reconstructive procedure such as Free Flap – 
Microvascular surgery has made surgery as the anchor role in management.  
 
With the invent of Radio sensitisers and Radio protectors, the 
radiotherapy as a modality of treatment has to be considered as deleterious 
effects are low.  
 
Role of adjuvant chemo and concomitant role of chemo & radiotherapy 
are analysed by various trials. 
 
Role of immunological agents such as Gefitinib and erlotinib and 
cetuximab are under trial.  
 
Effective multimodality management has come into vogue with 
Radiotherapy and surgery have definitive role along with doubtful role of 
chemotherapy has reduced the morbidity of oral cancers.  
 
Future developments in nanotechnology and directed therapies will 
alter the diagnosis and treatment of oral cancers relative to contemporary 
treatment modalities.     
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The best way to cure is by prevention.  Screening of high risk group (ie) 
those who are in the Habit of betel nut & tobacco chewing in general 
population, should be done. 
 
Dental surgeons and general practioners have a vital role with early 
detection of oral lesions and referral to higher centers for proper 
management.  
 
Health education through mass media and posters in Health centers 
and dispensaries on the ill effects of Tobacco / Alcohol / Betel nut in a large 
scale by Government and Non-Government organizations will create 
awareness and help in prevention.   
 
Younger population is to be educated by mass media with a ban on 
advertisement of Tobacco, Alcohol and screening camps will also be useful.    
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CLINICAL STAGING  TREATMENT OF PRIMARY AND NECK FOLLOW – UP 
 
 Excision of primary + 
unilateral or bilateral selective 
neck dissection 
(reconstruction as indicated) 
Excision of primary, ipsilateral 
comprehensive neck 
dissection + contralateral 
selective neck dissection 
(reconstruction as indicated)  
Excision of primary and 
bilateral comprehensive neck 
dissection (reconstruction as 
indicated)  
N2c 
(bilateral)
N1, 
N2a-b,  
N3 
N0 
Surgery 
External RT +  
brachytherapy 
Resectable 
(T3, T4 N0, 
Any T,  
N1-N3) 
Primary site: 
complete 
response  
Primary site: 
< complete 
response  
Residual 
neck mass 
Complete 
response of 
neck
Salvage surgery + neck 
dissection as indicated  
N1  
(initial stage) 
N2-3 
(initial stage) 
Observe 
 
Observe or Neck 
dissection  
(for selective vs. 
comprehensive) 
Neck dissection  
(for selective Vs. 
comprehensive) 
• T4 
• Close / positive margins 
• Perineural / lymphatic / 
vascular invasion 
• Multiple positive nodes 
• Extracapsular spread 
 
One positive node 
without adverse 
features  
Adjuvant 
RT 
Optional
Adjuvant 
RT 
Physical exam 
• Year 1 
every 1-3 
months  
• Year 2 
every 2-4 
months  
• Year 3-5 
every 4-6 
months  
• >5 Years 
every 6-12 
months  
 
CLINICAL STAGING TREATMENT OF PRIMARY & NECK  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Newly diagnosed 
Unresectable (M0); 
T4b, N any, or N+ 
unresectable 
Clinical trial 
preferred 
Standard 
therapy 
Concurrent cisplatin 
chemotherapy + RT 
or 
Induction Chemotherapy 
followed by RT  
Induction chemotherapy   
followed by RT  
or  
Definitive RT 
Definitive RT 
or  
Best  
Supportive care  
Residual neck  
disease : Neck 
dissection, if feasible + 
primary site  
controlled  
TREATMENT ALGORITHM FOR CANCER OF THE ORAL CAVITY 
 
Clinical Staging  Treatment of Primary And Neck  Follow Up
 
 
T1-2, N0 or 
External-beam RT 
+ brachytherapy 
> 70 Gy to primary  
> 50 Gy to neck at risk 
Excision of primary 
(preferred)+  
+ unilateral or bilateral 
neck dissection  
or 
One positive node 
without adverse 
features 
• T3 – 4  
• Close / Positive / 
margins  
• Perineural / 
lymphatic / 
vascular invasion  
• Multiple positive 
nodes  
• Extracapsular 
spread 
Residual disease  Salvage Surgery  
Adjuvant RT 
optional  
Resectable  
T3, N0 
Excision of primary 
and reconstruction as 
indicated and 
unilateral or bilateral 
selective neck 
dissection 
Adjuvant RT 
or 
Chemo / RT 
Adjuvant RT 
or 
Chemo / RT 
Physical exam 
• Year 1 
every 1-3 months  
• Year 2 
every 2-4 months  
• Year 3-5 
every 4-6 months  
• > 5 Years 
every 6-12 months  
 
Chest imaging  
annually, or earlier if 
clinically indicated  
TSH every 6- 12 
months if neck irradiated  
 
 
Clinical Staging  Treatment of Primary And Neck  Follow Up
 
 
 
Resectable  
T1-3, N1-3 
Surgery 
(preferred) 
External RT + 
brachytherapy + 
neck dissection  
Chemotherapy  
/ RT 
or 
or 
N1,  
N2a-b 
N3 
N2c 
(bilateral) 
Excision of primary, ipsilateral 
comprehensive neck dissection 
+ contralateral selective neck 
dissection reconstruction as 
indicated)  
Excision of primary and 
bilateral comprehensive 
neck dissection 
Primary site : 
complete 
response  
Primary site : 
< complete 
response  
Salvage surgery +  
neck dissection as indicated  
Complete 
response 
of neck 
Residual 
neck 
mass 
Neck dissection  
for selective vs. 
comprehensive  
N1 
 (initial stage) 
N2-3 
 (initial stage) 
Observe 
Observe or  
Neck Dissection 
(for selective vs. 
Comprehensive)  
One positive 
node without 
adverse features  
Adjuvant 
RT 
Optional 
• T3 – 4 
• Close / positive 
margins 
• Perinerual / lymphatic / 
vascular invasion   
• Multiple positive nodes 
• Extracapsular spread 
Adjuvant 
RT 
or 
Chemo/RT 
Physical exam 
• Year 1 
every 1-3 
months  
• Year 2 
every 2-4 
months  
• Year 3-5 
every 4-6 
months  
• > 5 Years 
every 6-12 
months  
 
Chest imaging  
annually, or 
earlier if 
clinically 
indicated  
TSH every 6- 12 
months if neck 
irradiated  
 
 
 
Clinical Staging  Treatment of Primary And Neck  Follow Up 
 
 
 
Resectable  
T4 Any N 
Surgery 
+ RT 
Chemo 
therapy /  
RT  
or Primary site : 
complete  
response  
Primary 
site :  
< complete 
response  
Residual 
neck mass 
Complete 
response 
of neck 
N1  
(initial stage) 
N2-3  
(initial stage) 
Neck dissection 
(selective vs. 
comprehensive)   
Observe 
Observe or 
Neck dissection 
(selective vs. 
comprehensive) 
Salvage surgery +  
neck dissection as indicated  
Resectable 
poor medical / 
surgical risk  
External RT + 
brachy therapy  
Physical exam 
• Year 1 
every 1-3 months  
• Year 2 
every 2-4 months  
• Year 3-5 
every 4-6 months  
• > 5 Years 
every 6-12 months  
 
Chest imaging  
annually, or earlier if 
clinically indicated  
TSH every 6- 12 
months if neck irradiated  
 
 
 
TREATMENT ALGORITHM FOR CANCER OF THE LIP  
 
 
CLINICAL STAGING  TREATMENT OF PRIMARY AND NECK FOLLOW – UP
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Positive margins Reexcision or RT* 
Perineural / vascular 
lymphatic invasion RT* 
No adverse 
pathologic findings 
External-beam  
RT > 50 Gy +  
brachytherapy  
or 
Brachytherapy  
alone 
or  
External-beam  
RT > 66 Gy 
Surgical 
excision 
Physical exam :  
¾ Year 1,  
every 1-3 months  
¾ Year 2,  
every 2-4 months  
¾ Year 3-5,  
every 4-6 months  
¾ > 5 Year,  
every 6-12 months 
Residual or 
recurrent 
tumor post-RT 
Surgery / 
reconstruction 
[T1 -2, N0] 
